ICU Medical, Inc. — Q3 2020 Form 10-Q
Business context and reporting period. The filing covers the quarter and nine months ended September 30, 2020. ICU Medical develops, manufactures and sells infusion therapy, IV solutions and critical-care products. Results were affected by COVID-19-related changes in hospital admissions and procedures.
Financial performance
Amounts below are in millions of dollars except per-share data and percentages.
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $318.6 | $307.5 | $950.6 | $950.7 |
| Gross profit / margin | $113.9 / 35.8% | $118.6 / 38.6% | $341.6 / 35.9% | $357.7 / 37.6% |
| Operating income | $25.5 | $32.9 | $71.1 | $89.5 |
| Net income | $25.0 | $26.6 | $60.7 | $80.4 |
| Diluted EPS | $1.16 | $1.24 | $2.82 | $3.73 |
| Operating cash flow | Not separately stated | Not separately stated | $144.2 | $53.1 |
- Q3 revenue increased 3.6% year over year, while nine-month revenue was essentially unchanged. Q3 Infusion Systems revenue rose 12.0%; Infusion Consumables declined 3.1%. For the first nine months, Infusion Systems rose 9.6%, while IV Solutions fell 5.9% and Infusion Consumables fell 2.1%.
- Gross margin contracted in both comparison periods. Management cited lower IV Solutions manufacturing volumes, unfavorable product mix and increased product-quality costs.
- Cash, cash equivalents and short-term investments totaled $363.5 at quarter-end, up from $292.6 at December 31, 2019. Current assets were $900.1 and current liabilities $185.4.
- The company had no borrowings at September 30 and $150.0 of availability on its revolving credit facility, which matures in November 2022. It reported compliance with financial covenants. Nine-month capital expenditures were $62.4.
Material changes and unusual items
- Operating cash flow increased to $144.2 from $53.1, with improved working-capital movements, notably collections of receivables and lower inventory. These benefits were partly offset by lower accounts payable and accrued liabilities.
- Nine-month net income was lower year over year. The comparison includes a $47.4 million 2019 gain from reducing the HIS acquisition earn-out liability; in 2020 the Pursuit earn-out fair value increase generated $7.0 million of expense. Nine-month restructuring, strategic transaction and integration costs also fell to $22.9 from $69.4.
- The Pursuit earn-out liability was $24.3 at quarter-end, up from $17.3 at year-end, reflecting changed assumptions in its valuation model. Pfizer disputes ICU Medical’s conclusion that no payment is due under the separate HIS earn-out; unresolved matters may proceed to binding arbitration.
- During March, the company borrowed $150.0 under its revolver as a precaution amid COVID-19 uncertainty and repaid it in full in September. No shares were repurchased under the $100.0 million authorization through September 30.
Outlook, commentary and risks
- Management estimated 2020 capital expenditures of approximately $85–$90 million and stated existing cash and expected operating cash flows should fund operations for the next 12 months. This is not a revenue or earnings forecast.
- COVID-19 reduced hospital admissions and procedural volumes, weighing on disposable products, including Infusion Consumables and IV Solutions, while demand for infusion pump hardware increased. The company also cited added employee compensation and protective-equipment costs, partly offset by lower travel and discretionary spending. Management said the pandemic’s future impact could not be reasonably quantified.
- Key risks include further demand or supply-chain disruption, facility interruptions, customer payment difficulties, delayed hospital implementations, possible over-purchasing followed by weaker demand, foreign-exchange volatility and constrained access to customers. The company reported $6.0 million of net foreign-exchange losses for the nine months.
- Other items to monitor include the Pfizer earn-out dispute, the variable Pursuit earn-out valuation, product-quality costs, foreign currency exposure and credit-facility covenant restrictions. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether hospital activity and demand recover, and how product-line trends develop after Q3.
- Whether gross margins stabilize given manufacturing volume, mix and quality-cost pressures.
- How much of operating cash-flow improvement reflects sustainable operations versus working-capital timing.
- The outcome and potential financial effect of the Pfizer HIS earn-out dispute and the evolving Pursuit earn-out obligation.
- Whether planned capital expenditures, COVID-19 effects and currency movements alter liquidity or the company’s stated 12-month funding expectations.